Correction (DOI:10.1016/j.ahj.2007.12.034);Antiplatelet drug nonresponsiveness

American Heart Journal

Volumn 155, Issue 4, 2008, Pages 591-599

  Gladding, Patrick ^a   Webster, Mark ^a   Ormiston, John ^a   Olsen, Sarah ^a   White, Harvey ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

11 OXOTHROMBOXANE B2; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CILOSTAZOL; CLOPIDOGREL; CREATINE KINASE MB; DIPYRIDAMOLE; FIBRINOGEN RECEPTOR ANTAGONIST; PHOSPHODIESTERASE INHIBITOR; PURINERGIC P2Y12 RECEPTOR; PURINERGIC RECEPTOR BLOCKING AGENT; TICLOPIDINE; TROPONIN I;

ACUTE CORONARY SYNDROME; CORONARY ARTERY DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; LOADING DRUG DOSE; PHARMACODYNAMICS; PHARMACOGENOMICS; PRIORITY JOURNAL; REVIEW; TACHYPHYLAXIS; THROMBOCYTE FUNCTION; THROMBOELASTOGRAPHY;

EID: 40849124575     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2008.07.013     Document Type: Erratum

References (94)

1. Helgason C.M., Tortorice K.L., Winkler S.R., et al. Aspirin response and failure in cerebral infarction. Stroke 24 (1993) 345-350
2. Muller I., Besta F., Schulz C., et al. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 89 (2003) 783-787
3. Madan M., Berkowitz S.D., Christie D.J., et al. Rapid assessment of glycoprotein IIb/IIIa blockade with the platelet function analyzer (PFA-100) during percutaneous coronary intervention. Am Heart J 141 (2001) 226-233
4. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Bmj 324 (2002) 71-86
5. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 348 (1996) 1329-1339
6. Mehta S.R., Yusuf S., Peters R.J., et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358 (2001) 527-533
7. Yusuf S., Zhao F., Mehta S.R., et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345 (2001) 494-502
8. Sabatine M.S., Cannon C.P., Gibson C.M., et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 352 (2005) 1179-1189
9. Lev E.I., Patel R.T., Maresh K.J., et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol 47 (2006) 27-33
10. Gum P.A., Kottke-Marchant K., Welsh P.A., et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 41 (2003) 961-965
11. Michelson A.D. Platelet function testing in cardiovascular diseases. Circulation 110 (2004) e489-e493
12. Martin C.P., and Talbert R.L. Aspirin resistance: an evaluation of current evidence and measurement methods. Pharmacotherapy 25 (2005) 942-953
13. Goodall A. The role of platelets and antiplatelet therapy in atherothrombotic disease. Br J Cardiol 9 Suppl 8 (2002) S2-S7
14. Wiviott S.D., Braunwald E., McCabe C.H., et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357 (2007) 2001-2015
15. Chackalamannil S., Ahn H.S., Xia Y., et al. Potent non-peptide thrombin receptor antagonists. Curr Med Chem Cardiovasc Hematol Agents 1 (2003) 37-45
16. Gurbel P.A. The relationship of platelet reactivity to the occurrence of post-stenting ischemic events: emergence of a new cardiovascular risk factor. Rev Cardiovasc Med 7 Suppl 4 (2006) S20-S28
17. Chan A.W., Moliterno D.J., Berger P.B., et al. Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoProGive Similar Efficacy Outcome Trial (TARGET). J Am Coll Cardiol 42 (2003) 1188-1195
18. Gurbel P.A., Bliden K.P., Zaman K.A., et al. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. Circulation 111 (2005) 1153-1159
19. Andre P., Delaney S.M., LaRocca T., et al. P2Y12 regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries. J Clin Invest 112 (2003) 398-406
20. Gurbel P.A., and Tantry U.S. Clopidogrel resistance?. Thromb Res 120 (2006) 311-321
21. Gurbel P.A., Bliden K.P., DiChiara J., et al. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation 115 (2007) 3156-3164
22. Harrison P. Platelet function analysis. Blood Rev 19 (2005) 111-123
23. Eikelboom J.W., Hirsh J., Weitz J.I., et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 105 (2002) 1650-1655
24. Geiger J., Brich J., Honig-Liedl P., et al. Specific impairment of human platelet P2Y(AC) ADP receptor-mediated signaling by the antiplatelet drug clopidogrel. Arterioscler Thromb Vasc Biol 19 (1999) 2007-2011
25. Dyszkiewicz-Korpanty A.M., Frenkel E.P., and Sarode R. Approach to the assessment of platelet function: comparison between optical-based platelet-rich plasma and impedance-based whole blood platelet aggregation methods. Clin Appl Thromb Hemost 11 (2005) 25-35
26. Schlammadinger A., Kerenyi A., Muszbek L., et al. Comparison of the O'Brien filter test and the PFA-100 platelet analyzer in the laboratory diagnosis of von Willebrand's disease. Thromb Haemost 84 (2000) 88-92
27. Hayward C.P., Harrison P., Cattaneo M., et al. Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function: reply to a rebuttal. J Thromb Haemost 4 (2006) 1432
28. van Werkum J.W., van der Stelt C.A., Seesing T.H., et al. A head-to-head comparison between the VerifyNow P2Y12 assay and light transmittance aggregometry for monitoring the individual platelet response to clopidogrel in patients undergoing elective percutaneous coronary intervention. J Thromb Haemost 4 (2006) 2516-2518
29. Coleman J.L., Wang J.C., and Simon D.I. Determination of individual response to aspirin therapy using the Accumetrics Ultegra RFPA-ASA system. Point of Care 3 (2004) 77-82
30. Wheeler G.L., Braden G.A., Steinhubl S.R., et al. The Ultegra rapid platelet-function assay: comparison to standard platelet function assays in patients undergoing percutaneous coronary intervention with abciximab therapy. Am Heart J 143 (2002) 602-611
31. Frelinger III A.L., Furman M.I., Linden M.D., et al. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. Circulation 113 (2006) 2888-2896
32. Grau A.J., Reiners S., Lichy C., et al. Platelet function under aspirin, clopidogrel, and both after ischemic stroke: a case-crossover study. Stroke 34 (2003) 849-854
33. Ziegler S., Maca T., Alt E., et al. Monitoring of antiplatelet therapy with the PFA-100 in peripheral angioplasty patients. Platelets 13 (2002) 493-497
34. Grundmann K., Jaschonek K., Kleine B., et al. Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J Neurol 250 (2003) 63-66
35. Macchi L., Christiaens L., Brabant S., et al. Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb Res 107 (2002) 45-49
36. ten Berg J.M., Gerritsen W.B., Haas F.J., et al. High-dose aspirin in addition to daily low-dose aspirin decreases platelet activation in patients before and after percutaneous coronary intervention. Thromb Res 105 (2002) 385-390
37. Gum P.A., Kottke-Marchant K., Poggio E.D., et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 88 (2001) 230-235
38. Andersen K., Hurlen M., Arnesen H., et al. Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res 108 (2002) 37-42
39. Gonzalez-Conejero R., Rivera J., Corral J., et al. Biological assessment of aspirin efficacy on healthy individuals: heterogeneous response or aspirin failure?. Stroke 36 (2005) 276-280
40. Sadiq P.A., Puri A., Dixit M., et al. Profile and prevalence of aspirin resistance in Indian patients with coronary artery disease. Indian Heart J 57 (2005) 658-661
41. Coleman J., Wang J., and Daniel S. Determination of individual response to aspirin therapy using the Accumetrics Ultegra RPFA-ASA system. Point of Care 3 (2004) 77-82
42. Serebruany V.L., Steinhubl S.R., Berger P.B., et al. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 45 (2005) 246-251
43. Gurbel P.A., Bliden K.P., Hiatt B.L., et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107 (2003) 2908-2913
44. Cotter G., Shemesh E., Zehavi M., et al. Lack of aspirin effect: aspirin resistance or resistance to taking aspirin?. Am Heart J 147 (2004) 293-300
45. Simon D.I., and Schmaier A.H. Sweet and sticky: diabetic platelets, enhanced reactivity, and cardiovascular risk. J Am Coll Cardiol 50 (2007) 1548-1550
46. Angiolillo D.J., Bernardo E., Sabate M., et al. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 50 (2007) 1541-1547
47. Tang M., Mukundan M., Yang J., et al. Antiplatelet agents aspirin and clopidogrel are hydrolyzed by distinct carboxylesterases, and clopidogrel is transesterificated in the presence of ethyl alcohol. J Pharmacol Exp Ther 319 (2006) 1467-1476
48. Cerletti C., Latini R., Del Maschio A., et al. Aspirin kinetics and inhibition of platelet thromboxane generation-relevance for a solution of the "aspirin dilemma". Thromb Haemost 53 (1985) 415-418
49. Bucchi F., Bodzenta A., de Gaetano G., et al. Effects of 1 gram oral or intravenous aspirin on urinary excretion of thromboxane B2 and 6-keto-PGF1 alpha in healthy subjects. Prostaglandins 32 (1986) 691-701
50. Frolich J.C. A classification of NSAIDs according to the relative inhibition of cyclooxygenase isoenzymes. Trends Pharmacol Sci 18 (1997) 30-34
51. Perneby C., Wallen N.H., Rooney C., et al. Dose- and time-dependent antiplatelet effects of aspirin. Thromb Haemost 95 (2006) 652-658
52. Savi P., Pereillo J.M., Uzabiaga M.F., et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 84 (2000) 891-896
53. Pereillo J.M., Maftouh M., Andrieu A., et al. Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab Dispos 30 (2002) 1288-1295
54. Brandt J.T., Close S.L., Iturria S.J., et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 5 (2007) 2429-2436
55. Lau W.C., Waskell L.A., Watkins P.B., et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 107 (2003) 32-37
56. Saw J., Steinhubl S.R., Berger P.B., et al. Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation 108 (2003) 921-924
57. von Beckerath N., Taubert D., Pogatsa-Murray G., et al. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) trial. Circulation 112 (2005) 2946-2950
58. Fromm M.F. P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int J Clin Pharmacol Ther 38 (2000) 69-74
59. Rao G.H., Johnson G.G., Reddy K.R., et al. Ibuprofen protects platelet cyclooxygenase from irreversible inhibition by aspirin. Arteriosclerosis 3 (1983) 383-388
60. Catella-Lawson F., Reilly M.P., Kapoor S.C., et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 345 (2001) 1809-1817
61. Livio M., Del Maschio A., Cerletti C., et al. Indomethacin prevents the long-lasting inhibitory effect of aspirin on human platelet cyclo-oxygenase activity. Prostaglandins 23 (1982) 787-796
62. Capone M.L., Sciulli M.G., Tacconelli S., et al. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J Am Coll Cardiol 45 (2005) 1295-1301
63. Maree A.O., Curtin R.J., Chubb A., et al. Cyclooxygenase-1 haplotype modulates platelet response to aspirin. J Thromb Haemost 3 (2005) 2340-2345
64. Jefferson B.K., Foster J.H., McCarthy J.J., et al. Aspirin resistance and a single gene. Am J Cardiol 95 (2005) 805-808
65. Lev E.I., Patel R.T., Guthikonda S., et al. Genetic polymorphisms of the platelet receptors P2Y(12), P2Y(1) and GP IIIa and response to aspirin and clopidogrel. Thromb Res 119 (2006) 355-360
66. Hollopeter G., Jantzen H.M., Vincent D., et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 409 (2001) 202-207
67. Fontana P., Dupont A., Gandrille S., et al. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation 108 (2003) 989-995
68. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., et al. Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel. Arterioscler Thromb Vasc Biol 26 (2006) 1895-1900
69. Hulot J.S., Bura A., Villard E., et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 108 (2006) 2244-2247
70. Taubert D., von Beckerath N., Grimberg G., et al. Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther 80 (2006) 486-501
71. Pamukcu B., Oflaz H., Onur I., et al. Clinical relevance of aspirin resistance in patients with stable coronary artery disease: a prospective follow-up study (PROSPECTAR). Blood Coagul Fibrinolysis 18 (2007) 187-192
72. Chen W.H., Cheng X., Lee P.Y., et al. Aspirin resistance and adverse clinical events in patients with coronary artery disease. Am J Med 120 (2007) 631-635
73. Chen W.H., Lee P.Y., Ng W., et al. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 43 (2004) 1122-1126
74. Marcucci R., Paniccia R., Antonucci E., et al. Usefulness of aspirin resistance after percutaneous coronary intervention for acute myocardial infarction in predicting one-year major adverse coronary events. Am J Cardiol 98 (2006) 1156-1159
75. Frossard M., Fuchs I., Leitner J.M., et al. Platelet function predicts myocardial damage in patients with acute myocardial infarction. Circulation 110 (2004) 1392-1397
76. Campo G., Valgimigli M., Gemmati D., et al. Value of platelet reactivity in predicting response to treatment and clinical outcome in patients undergoing primary coronary intervention: insights into the STRATEGY study. J Am Coll Cardiol 48 (2006) 2178-2185
77. Jacopo G., Elisabetta V., Silverio S., et al. Identification of platelet hyper-reactivity measured with a portable device immediately after percutaneous coronary intervention predicts in stent thrombosis. Thromb Res 121 (2007) 407-412
78. Poulsen T.S., Kristensen S.R., Korsholm L., et al. Variation and importance of aspirin resistance in patients with known cardiovascular disease. Thromb Res 120 (2006) 477-484
79. Valles J., Santos M.T., Fuset M.P., et al. Partial inhibition of platelet thromboxane A2 synthesis by aspirin is associated with myonecrosis in patients with ST-segment elevation myocardial infarction. Am J Cardiol 99 (2007) 19-25
80. Gurbel P.A., Bliden K.P., Guyer K., et al. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING study. J Am Coll Cardiol 46 (2005) 1820-1826
81. Gurbel P.A., Bliden K.P., Samara W., et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST study. J Am Coll Cardiol 46 (2005) 1827-1832
82. Geisler T., Langer H., Wydymus M., et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 27 (2006) 2420-2425
83. Cuisset T., Frere C., Quilici J., et al. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting. J Am Coll Cardiol 48 (2006) 1339-1345
84. Hochholzer W., Trenk D., Bestehorn H.P., et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 48 (2006) 1742-1750
85. Bliden K.P., DiChiara J., Tantry U.S., et al. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?. J Am Coll Cardiol 49 (2007) 657-666
86. Buonamici P., Marcucci R., Migliorini A., et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 49 (2007) 2312-2317
87. Patti G., Colonna G., Pasceri V., et al. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation 111 (2005) 2099-2106
88. Derry S., and Loke Y.K. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. Bmj 321 (2000) 1183-1187
89. Pulcinelli F.M., Pignatelli P., Celestini A., et al. Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients. J Am Coll Cardiol 43 (2004) 979-984
90. Von Beckerath N., Kastrati A., Wieczorek A., et al. A double-blind randomized comparison between two different clopidogrel maintenance doses after percutaneous coronary intervention (ISAR-CHOICE 2 trial). (abstr). Eur Heart J 27 (2006)
91. Cheng X., Chen W.H., and Simon D.I. Aspirin resistance or variable response or both?. Am J Cardiol 98 (2006) 11N-17N
92. Weerakkody G.J., Jakubowski J.A., Brandt J.T., et al. Comparison of speed of onset of platelet inhibition after loading doses of clopidogrel versus prasugrel in healthy volunteers and correlation with responder status. Am J Cardiol 100 (2007) 331-336
93. Wiviott S.D., Antman E.M., Winters K.J., et al. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation 111 (2005) 3366-3373
94. Wiviott S.D., Trenk D., Frelinger A.L., et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention; the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 116 (2007) 2923-2932